Skip to content

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
26.3×-20.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
AbbVie logo
AbbVieABBV
261×+221×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
+4.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
1.5×+0.3×
Arcus Biosciences logo
Arcus BiosciencesRCUS
5.2×+3.6×

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.09B+259%
Enterprise value$1.05B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Calculated from Corvus Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's price / book?
Corvus Pharmaceuticals (CRVS) reported price / book of 5.1× in Q1 2026.
How has Corvus Pharmaceuticals's price / book changed year-over-year?
Corvus Pharmaceuticals's price / book increased by 16.2% year-over-year, from 4.4× to 5.1×.
What is the long-term trend for Corvus Pharmaceuticals's price / book?
Over 5 years (2020 to 2025), Corvus Pharmaceuticals's price / book has grown at a 32.5% compound annual growth rate (CAGR), from 2.3× to 9.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.